Category: AlphaOV BLOG

Cancer treatment has entered an exciting new era with the latest study by Zhong et al., published in Cell, which showcases a hyperacute rejection-engineered oncolytic virus as a game-changing approach to treating refractory cancers. This innovative therapy, using a genetically modified Newcastle disease virus (NDV-GT), has demonstrated remarkable efficacy in both preclinical and clinical trials,…

At the JPMorgan 2025 Healthcare Conference, the field of oncolytic virus (OV) therapy is poised to be a significant topic, as the technology continues to gain attention for its promising potential in cancer treatment. Here’s a summary of the current and future progress of oncolytic virus therapies based on recent trends and discussions likely to…

At Alpha OV Therapeutics, we are on a mission to transform the way cancer is treated by leveraging the immense potential of oncolytic viruses. These unique and powerful viruses are engineered to selectively target and destroy cancer cells, offering a promising new frontier in the fight against solid tumors. As we continue to push the…